Inhibitors of indoleamine 2,3-dioxygenase: a review of novel patented lead compounds

Bibliography

• Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004;4:762-74
   PubMed Web of Science ®Google Scholar
• Munn DH, Zhou M, Attwood JT, Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998;281:1191-3
   PubMed Web of Science ®Google Scholar
• Uyttenhove C, Pilotte L, Theate I, Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003;9:1269-74
   PubMed Web of Science ®Google Scholar
• Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006;108:804-11
   PubMed Web of Science ®Google Scholar
• Shevach EM. CD4+CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2002;2:389-400
   PubMed Web of Science ®Google Scholar
• Rutella S, Danese S, Leone G. Regulatory T cells for immunotherapy of autoimmune diseases: from the bench to the bedside. Expert Opin Ther Pat 2005;15:1595-616
   Web of Science ®Google Scholar
• Niederkorn JY. Emerging concepts in CD8+ T regulatory cells. Curr Opin Immunol 2008;20:327-31
   PubMed Web of Science ®Google Scholar
• Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 2007;117:1155-66
   PubMed Web of Science ®Google Scholar
• Terabe M, Berzofsky JA. NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis. Trends Immunol 2007;28:491-6
   PubMed Web of Science ®Google Scholar
• Lu LF, Lind EF, Gondek DC, Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 2006;442:997-1002
   PubMed Web of Science ®Google Scholar
• Rutella S, Danese S, Leone G. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood 2006;108:1435-40
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Bronte V, Chen SH, The terminology issue for myeloid-derived suppressor cells. Cancer Res 2007;67:425
   PubMed Web of Science ®Google Scholar
• Marigo I, Dolcetti L, Serafini P, Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008;222:162-79
   PubMed Web of Science ®Google Scholar
• Lee JR, Dalton RR, Messina JL, Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Lab Invest 2003;83:1457-66
   PubMed Web of Science ®Google Scholar
• Munn DH, Sharma MD, Lee JR, Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002;297:1867-70
   PubMed Web of Science ®Google Scholar
• Di Pucchio T, Chatterjee B, Smed-Sorensen A, Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I. Nat Immunol 2008;9:551-7
   PubMed Web of Science ®Google Scholar
• Chen W, Liang X, Peterson AJ, The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol 2008;181:5396-404
   PubMed Web of Science ®Google Scholar
• Munn DH, Mellor AL. Chemokine receptor antagonists as therapuetic agents. US7465448B2; 2008
   Google Scholar
• Munn DH, Sharma MD, Hou D, Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 2004;114:280-90
   PubMed Web of Science ®Google Scholar
• Odemuyiwa SO, Ghahary A, Li Y, Cutting edge: human eosinophils regulate T cell subset selection through indoleamine 2,3-dioxygenase. J Immunol 2004;173:5909-13
   PubMed Web of Science ®Google Scholar
• Rutella S, Bonanno G, De Cristofaro R. Targeting indoleamine 2,3-dioxygense (IDO) to counteract tumour-induced immune dysfunction: from biochemistry to clinical development. Endocr Metab Immune Disord Drug Targets 2009;9:151-77
   Google Scholar
• Curti A, Trabanelli S, Salvestrini V, The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology. Blood 2009;113:2394-401
   PubMed Web of Science ®Google Scholar
• Prendergast GC. Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 2008;27:3889-900
   PubMed Web of Science ®Google Scholar
• Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 2007;117:1147-54
   PubMed Web of Science ®Google Scholar
• Lee JH, Torisu-Itakara H, Cochran AJ, Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clin Cancer Res 2005;11:107-12
   PubMed Web of Science ®Google Scholar
• von Bergwelt-Baildon MS, Popov A, Saric T, CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood 2006;108:228-37
   PubMed Web of Science ®Google Scholar
• Belladonna ML, Grohmann U, Guidetti P, Kynurenine pathway enzymes in dendritic cells initiate tolerogenesis in the absence of functional IDO. J Immunol 2006;177:130-7
   PubMed Web of Science ®Google Scholar
• Mellor AL, Munn DH. Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance. US20070048769A1; 2007
   Google Scholar
• Mellor AL, Munn DH. Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance. US20060292618A1; 2006
   Google Scholar
• Mellor AL, Munn DH. Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance. US20030194803A1; 2003
   Google Scholar
• Ball HJ, Yuasa HJ, Austin CJ, Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway. Int J Biochem Cell Biol 2009;41:467-71
   PubMed Web of Science ®Google Scholar
• Ball HJ, Sanchez-Perez A, Weiser S, Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene 2007;396:203-13
   PubMed Web of Science ®Google Scholar
• Metz R, Duhadaway JB, Kamasani U, Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res 2007;67:7082-7
   PubMed Web of Science ®Google Scholar
• Rongvaux A, Andris F, Van Gool F, Leo O. Reconstructing eukaryotic NAD metabolism. Bioessays 2003;25:683-90
   PubMed Web of Science ®Google Scholar
• Fallarino F, Grohmann U, Vacca C, T cell apoptosis by tryptophan catabolism. Cell Death Differ 2002;9:1069-77
   PubMed Web of Science ®Google Scholar
• Munn DH, Sharma MD, Mellor AL. Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol 2004;172:4100-10
   PubMed Web of Science ®Google Scholar
• Braun D, Longman RS, Albert ML. A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood 2005;106:2375-81
   PubMed Web of Science ®Google Scholar
• Takikawa O, Yoshida R, Kido R, Hayaishi O. Tryptophan degradation in mice initiated by indoleamine 2,3-dioxygenase. J Biol Chem 1986;261:3648-53
   PubMed Web of Science ®Google Scholar
• Miller CL, Llenos IC, Cwik M, Alterations in kynurenine precursor and product levels in schizophrenia and bipolar disorder. Neurochem Int 2008;52:1297-303
   PubMed Web of Science ®Google Scholar
• Kucharewicz I, Kasacka I, Pawlak D, The concentration of kynurenine in rat model of asthma. Folia Histochem Cytobiol 2008;46:199-203
   Google Scholar
• Carlin JM, Borden EC, Sondel PM, Byrne GI. Biologic-response-modifier-induced indoleamine 2,3-dioxygenase activity in human peripheral blood mononuclear cell cultures. J Immunol 1987;139:2414-18
   PubMed Web of Science ®Google Scholar
• Byrne GI, Lehmann LK, Kirschbaum JG, Induction of tryptophan degradation in vitro and in vivo: a gamma-interferon-stimulated activity. J Interferon Res 1986;6:389-96
   PubMedGoogle Scholar
• Ozaki Y, Edelstein MP, Duch DS. Induction of indoleamine 2,3-dioxygenase: a mechanism of the antitumor activity of interferon gamma. Proc Natl Acad Sci USA 1988;85:1242-6
   PubMed Web of Science ®Google Scholar
• Taylor MW, Feng GS. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J 1991;5:2516-22
   PubMed Web of Science ®Google Scholar
• Du MX, Sotero-Esteva WD, Taylor MW. Analysis of transcription factors regulating induction of indoleamine 2,3-dioxygenase by IFN-gamma. J Interferon Cytokine Res 2000;20:133-42
   PubMedGoogle Scholar
• Tas SW, Vervoordeldonk MJ, Hajji N, Noncanonical NF-kappaB signaling in dendritic cells is required for indoleamine 2,3-dioxygenase (IDO) induction and immune regulation. Blood 2007;110:1540-9
   PubMed Web of Science ®Google Scholar
• Lim H, Paria BC, Das SK, Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell 1997;91:197-208
   PubMed Web of Science ®Google Scholar
• Basu GD, Tinder TL, Bradley JM, Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO. J Immunol 2006;177:2391-402
   PubMed Web of Science ®Google Scholar
• Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 2003;4:431-6
   PubMed Web of Science ®Google Scholar
• Akasaki Y, Liu G, Chung NH, Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma. J Immunol 2004;173:4352-9
   PubMed Web of Science ®Google Scholar
• Sayama S, Yoshida R, Oku T, Inhibition of interferon-mediated induction of indoleamine 2,3-dioxygenase in mouse lung by inhibitors of prostaglandin biosynthesis. Proc Natl Acad Sci USA 1981;78:7327-30
   PubMed Web of Science ®Google Scholar
• Marshall B, Keskin DB, Mellor AL. Regulation of prostaglandin synthesis and cell adhesion by a tryptophan catabolizing enzyme. BMC Biochem 2001;2:5
   PubMedGoogle Scholar
• Mukherjee P, Basu GD, Tinder TL, Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. J Immunol 2009;182:216-24
   PubMed Web of Science ®Google Scholar
• Albert M, Braun D. Control of indoleamine 2,3-dioxygenase expression and activity. WO2006056304A2; 2006
   Google Scholar
• Galimi F, Cottone E, Vigna E, Hepatocyte growth factor is a regulator of monocyte-macrophage function. J Immunol 2001;166:1241-7
   Google Scholar
• Rutella S, Bonanno G, Procoli A, Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. Blood 2006;108:218-27
   PubMed Web of Science ®Google Scholar
• Du W, Hattori Y, Yamada T, NK4, an antagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells: molecular targeting of angiogenic growth factor. Blood 2007;109:3042-9
   PubMed Web of Science ®Google Scholar
• Okunishi K, Dohi M, Nakagome K, A novel role of hepatocyte growth factor as an immune regulator through suppressing dendritic cell function. J Immunol 2005;175:4745-53
   PubMed Web of Science ®Google Scholar
• Okunishi K, Dohi M, Fujio K, Hepatocyte growth factor significantly suppresses collagen-induced arthritis in mice. J Immunol 2007;179:5504-13
   PubMed Web of Science ®Google Scholar
• Alberati-Giani D, Malherbe P, Ricciardi-Castagnoli P, Differential regulation of indoleamine 2,3-dioxygenase expression by nitric oxide and inflammatory mediators in IFN-gamma-activated murine macrophages and microglial cells. J Immunol 1997;159:419-26
   PubMed Web of Science ®Google Scholar
• Thomas SR, Mohr D, Stocker R. Nitric oxide inhibits indoleamine 2,3-dioxygenase activity in interferon-gamma primed mononuclear phagocytes. J Biol Chem 1994;269:14457-64
   PubMed Web of Science ®Google Scholar
• Yuan W, Collado-Hidalgo A, Yufit T, Modulation of cellular tryptophan metabolism in human fibroblasts by transforming growth factor-beta: selective inhibition of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA synthetase gene expression. J Cell Physiol 1998;177:174-86
   PubMed Web of Science ®Google Scholar
• Belladonna ML, Volpi C, Bianchi R, Cutting edge: autocrine TGF-beta sustains default tolerogenesis by IDO-competent dendritic cells. J Immunol 2008;181:5194-8
   PubMed Web of Science ®Google Scholar
• Belladonna ML, Orabona C, Grohmann U, Puccetti P. TGF-beta and kynurenines as the key to infectious tolerance. Trends Mol Med 2009;15:41-9
   PubMed Web of Science ®Google Scholar
• Orabona C, Pallotta MT, Volpi C, SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. Proc Natl Acad Sci USA 2008;105:20828-33
   PubMed Web of Science ®Google Scholar
• Munn DH, Mellor AL. Regulation of T cell-mediated immunity by tryptophan. US6451840B1; 2002a
   Google Scholar
• Munn DH, Mellor AL. Regulation of T cell-mediated immunity by tryptophan. US6482416B2; 2002b
   Google Scholar
• Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin Cancer Biol 2005;15:254-66
   PubMed Web of Science ®Google Scholar
• Seymour RL, Ganapathy V, Mellor AL, Munn DH. A high-affinity, tryptophan-selective amino acid transport system in human macrophages. J Leukoc Biol 2006;80:1320-7
   PubMedGoogle Scholar
• Kaper T, Looger LL, Takanaga H, Nanosensor detection of an immunoregulatory tryptophan influx/kynurenine efflux cycle. PLoS Biol 2007;5:e257
   Web of Science ®Google Scholar
• Kaper T, Platten M, Steinman L, Frommer W. TRP/HIS exchange and kynurenine induced TRP transport. US20080227140A1; 2008
   Google Scholar
• Frumento G, Rotondo R, Tonetti M, Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 2002;196:459-68
   PubMed Web of Science ®Google Scholar
• Molano A, Illarionov PA, Besra GS, Modulation of invariant natural killer T cell cytokine responses by indoleamine 2,3-dioxygenase. Immunol Lett 2008;117:81-90
   PubMed Web of Science ®Google Scholar
• Adikari SB, Lian H, Link H, Interferon-gamma-modified dendritic cells suppress B cell function and ameliorate the development of experimental autoimmune myasthenia gravis. Clin Exp Immunol 2004;138:230-6
   PubMed Web of Science ®Google Scholar
• Manlapat AK, Kahler DJ, Chandler PR, Cell-autonomous control of interferon type I expression by indoleamine 2,3-dioxygenase in regulatory CD19+ dendritic cells. Eur J Immunol 2007;37:1064-71
   PubMed Web of Science ®Google Scholar
• Romani L, Fallarino F, De Luca A, Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature 2008;451:211-15
   PubMed Web of Science ®Google Scholar
• Fallarino F, Grohmann U, You S, The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 2006;176:6752-61
   PubMed Web of Science ®Google Scholar
• Puccetti P, Grohmann U. IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation. Nat Rev Immunol 2007;7:817-23
   PubMed Web of Science ®Google Scholar
• Fallarino F, Grohmann U, Hwang KW, Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 2003;4:1206-12
   PubMed Web of Science ®Google Scholar
• Chen W, Blazar BR, Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase pathways in the generation of regulatory T cells. US20090155311A1; 2009
   Google Scholar
• Munn DH, Shafizadeh E, Attwood JT, Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999;189:1363-72
   PubMed Web of Science ®Google Scholar
• Mellor AL, Munn DH. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today 1999;20:469-73
   PubMedGoogle Scholar
• Terness P, Bauer TM, Rose L, Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med 2002;196:447-57
   PubMed Web of Science ®Google Scholar
• Munn DH, Sharma MD, Baban B, GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 2005;22:633-42
   PubMed Web of Science ®Google Scholar
• Munn DH, Mellor AL. Regulation of T cell-mediated immunity by tryptophan. US7160539B2; 2007
   Google Scholar
• Lob S, Konigsrainer A, Rammensee HG, Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat Rev Cancer 2009;9:445-52
   PubMed Web of Science ®Google Scholar
• Weaver CT, Harrington LE, Mangan PR, Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006;24:677-88
   PubMed Web of Science ®Google Scholar
• Sharma MD, Hou DY, Liu Y, Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood 2009;113:6102-11
   PubMed Web of Science ®Google Scholar
• Muller AJ, Malachowski WP, Prendergast GC. Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors. Expert Opin Ther Targets 2005;9:831-49
   PubMed Web of Science ®Google Scholar
• Munn DH, Mellor AL. IDO and tolerance to tumors. Trends Mol Med 2004;10:15-8
   PubMed Web of Science ®Google Scholar
• Munn DH. Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation. Curr Opin Immunol 2006;18:220-5
   PubMed Web of Science ®Google Scholar
• Katz JB, Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev 2008;222:206-21
   PubMed Web of Science ®Google Scholar
• Brandacher G, Perathoner A, Ladurner R, Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 2006;12:1144-51
   PubMed Web of Science ®Google Scholar
• Huang A, Fuchs D, Widner B, Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br J Cancer 2002;86:1691-6
   PubMed Web of Science ®Google Scholar
• Witkiewicz A, Williams T, Cozzitorto J, Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection. J Am Coll Surg 2008;206:849-54
   PubMed Web of Science ®Google Scholar
• Nakamura T, Shima T, Saeki A, Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer. Cancer Sci 2007;98:874-81
   PubMed Web of Science ®Google Scholar
• Ino K, Yamamoto E, Shibata K, Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: Its association with disease progression and survival. Clin Cancer Res 2008;14:2310-17
   PubMed Web of Science ®Google Scholar
• Curti A, Aluigi M, Pandolfi S, Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. Leukemia 2007;21:353-5
   Google Scholar
• Okamoto A, Nikaido T, Ochiai K, Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res 2005;11:6030-9
   PubMed Web of Science ®Google Scholar
• Takao M, Okamoto A, Nikaido T, Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer. Oncol Rep 2007;17:1333-9
   PubMed Web of Science ®Google Scholar
• Bonanno G, Corallo M, Mariotti A, Indoleamine 2,3-dioxygenase (IDO) is expressed by multiple myeloma plasma cells and promotes the differentiation of regulatory T cells: investigations into the role of hepatocyte growth factor. Blood 2008;112:1680A
   Google Scholar
• Prendergast GC, Metz R, Muller AJ. IDO recruits Tregs in melanoma. Cell Cycle 2009;8:1818-19
   PubMed Web of Science ®Google Scholar
• Szanto S, Koreny T, Mikecz K, Inhibition of indoleamine 2,3-dioxygenase-mediated tryptophan catabolism accelerates collagen-induced arthritis in mice. Arthritis Res Ther 2007;9:R50
   PubMed Web of Science ®Google Scholar
• Scott GN, DuHadaway J, Pigott E, The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity. J Immunol 2009;182:7509-17
   PubMed Web of Science ®Google Scholar
• Korganow AS, Ji H, Mangialaio S, From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity 1999;10:451-61
   PubMed Web of Science ®Google Scholar
• Zhu L, Ji F, Wang Y, Synovial autoreactive T cells in rheumatoid arthritis resist IDO-mediated inhibition. J Immunol 2006;177:8226-33
   PubMedGoogle Scholar
• Pertovaara M, Hasan T, Raitala A, Indoleamine 2,3-dioxygenase activity is increased in patients with systemic lupus erythematosus and predicts disease activation in the sunny season. Clin Exp Immunol 2007;150:274-8
   PubMed Web of Science ®Google Scholar
• Mohib K, Wang S, Guan Q, Indoleamine 2,3-dioxygenase expression promotes renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 2008;295:F226-34
   Web of Science ®Google Scholar
• Pawlak K, Mysliwiec M, Pawlak D. Hypercoagulability is independently associated with kynurenine pathway activation in dialysed uraemic patients. Thromb Haemost 2009;102:49-55
   PubMed Web of Science ®Google Scholar
• Pawlak K, Domaniewski T, Mysliwiec M, Pawlak D. Kynurenines and oxidative status are independently associated with thrombomodulin and von Willebrand factor levels in patients with end-stage renal disease. Thromb Res 2009;124:452-7
   Google Scholar
• Jung ID, Lee MG, Chang JH, Blockade of indoleamine 2,3-dioxygenase protects mice against lipopolysaccharide-induced endotoxin shock. J Immunol 2009;182:3146-54
   PubMedGoogle Scholar
• Muller AJ, Sharma MD, Chandler PR, Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc Natl Acad Sci USA 2008;105:17073-8
   PubMed Web of Science ®Google Scholar
• Logters TT, Laryea MD, Altrichter J, Increased plasma kynurenine values and kynurenine: tryptophan ratios after major trauma are early indicators for the development of sepsis. Shock 2008; published online 22 December 2008, doi: 10.1097/SHK.0b013e3181994bbf
   Google Scholar
• Huttunen R, Syrjanen J, Aittoniemi J, High activity of indoleamine 2,3 dioxygenase enzyme predicts disease severity and case fatality in bacteremic patients. Shock 2009; published online 18 May 2009, doi: 10.1097/SHK.0b013e3181ad3195
   Google Scholar
• Niinisalo P, Raitala A, Pertovaara M, Indoleamine 2,3-dioxygenase activity associates with cardiovascular risk factors: the Health 2000 study. Scand J Clin Lab Invest 2008;68:767-70
   PubMed Web of Science ®Google Scholar
• Pertovaara M, Raitala A, Juonala M, Indoleamine 2,3-dioxygenase enzyme activity correlates with risk factors for atherosclerosis: the Cardiovascular Risk in Young Finns Study. Clin Exp Immunol 2007;148:106-11
   PubMed Web of Science ®Google Scholar
• Sakash JB, Byrne GI, Lichtman A, Libby P. Cytokines induce indoleamine 2,3-dioxygenase expression in human atheroma-asociated cells: implications for persistent Chlamydophila pneumoniae infection. Infect Immun 2002;70:3959-61
   PubMed Web of Science ®Google Scholar
• Barth MC, Ahluwalia N, Anderson TJ, Kynurenic acid triggers firm arrest of leukocytes to vascular endothelium under flow conditions. J Biol Chem 2009;284:19189-95
   PubMed Web of Science ®Google Scholar
• Kanth VR, Lavanya K, Srinivas J. Elevated expression of indoleamine 2,3-dioxygenase (IDO) and accumulation of kynurenic acid in the pathogenesis of STZ-induced diabetic cataract in Wistar rats. Curr Eye Res 2009;34:274-81
   PubMed Web of Science ®Google Scholar
• Mailankot M, Staniszewska MM, Butler H, Indoleamine 2,3-dioxygenase overexpression causes kynurenine-modification of proteins, fiber cell apoptosis and cataract formation in the mouse lens. Lab Invest 2009;89:498-512
   PubMed Web of Science ®Google Scholar
• Grohmann U, Volpi C, Fallarino F, Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy. Nat Med 2007;13:579-86
   PubMed Web of Science ®Google Scholar
• Taher YA, Piavaux BJ, Gras R, Indoleamine 2,3-dioxygenase-dependent tryptophan metabolites contribute to tolerance induction during allergen immunotherapy in a mouse model. J Allergy Clin Immunol 2008;121:983-91 e2
   PubMed Web of Science ®Google Scholar
• Xu H, Oriss TB, Fei M, Indoleamine 2,3-dioxygenase in lung dendritic cells promotes Th2 responses and allergic inflammation. Proc Natl Acad Sci USA 2008;105:6690-95
   PubMed Web of Science ®Google Scholar
• Jasperson LK, Bucher C, Panoskaltsis-Mortari A, Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality. Blood 2008;111:3257-65
   PubMed Web of Science ®Google Scholar
• Danese S. Nonimmune cells in inflammatory bowel disease: from victim to villain. Trends Immunol 2008;29:555-64
   PubMedGoogle Scholar
• Jasperson LK, Bucher C, Panoskaltsis-Mortari A, Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality. Blood 2009; published online 14 October 2009, doi: 10.1182/blood-2009-06-227587
   Google Scholar
• Harrington L, Srikanth CV, Antony R, Deficiency of indoleamine 2,3-dioxygenase enhances commensal-induced antibody responses and protects against Citrobacter rodentium-induced colitis. Infect Immun 2008;76:3045-53
   PubMed Web of Science ®Google Scholar
• Cherayil BJ. Indoleamine 2,3-dioxygenase in intestinal immunity and inflammation. Inflamm Bowel Dis 2009;15:1391-6
   Google Scholar
• Zelante T, Fallarino F, Bistoni F, Indoleamine 2,3-dioxygenase in infection: the paradox of an evasive strategy that benefits the host. Microbes Infect 2009;11:133-41
   PubMed Web of Science ®Google Scholar
• Pfefferkorn ER. Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc Natl Acad Sci USA 1984;81:908-12
   PubMed Web of Science ®Google Scholar
• Bodaghi B, Goureau O, Zipeto D, Role of IFN-gamma-induced indoleamine 2,3 dioxygenase and inducible nitric oxide synthase in the replication of human cytomegalovirus in retinal pigment epithelial cells. J Immunol 1999;162:957-64
   PubMed Web of Science ®Google Scholar
• Leonhardt RM, Lee SJ, Kavathas PB, Cresswell P. Severe tryptophan starvation blocks onset of conventional persistence and reduces reactivation of Chlamydia trachomatis. Infect Immun 2007;75:5105-17
   PubMed Web of Science ®Google Scholar
• Manches O, Munn D, Fallahi A, HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism. J Clin Invest 2008;118:3431-9
   PubMed Web of Science ®Google Scholar
• Boasso A, Herbeuval JP, Hardy AW, HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells. Blood 2007;109:3351-9
   PubMedGoogle Scholar
• Boasso A, Vaccari M, Hryniewicz A, Regulatory T-cell markers, indoleamine 2,3-dioxygenase, and virus levels in spleen and gut during progressive simian immunodeficiency virus infection. J Virol 2007;81:11593-603
   PubMed Web of Science ®Google Scholar
• Samikkannu T, Saiyed ZM, Rao KV, Differential regulation of indoleamine-2,3-dioxygenase (IDO) by HIV type 1 clade B and C Tat protein. AIDS Res Hum Retroviruses 2009;25:329-35
   Google Scholar
• Potula R, Poluektova L, Knipe B, Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis. Blood 2005;106:2382-90
   PubMed Web of Science ®Google Scholar
• Boasso A, Vaccari M, Fuchs D, Combined effect of antiretroviral therapy and blockade of IDO in SIV-infected rhesus macaques. J Immunol 2009;182:4313-20
   PubMed Web of Science ®Google Scholar
• Saito K, Markey SP, Heyes MP. Chronic effects of gamma-interferon on quinolinic acid and indoleamine-2,3-dioxygenase in brain of C57BL6 mice. Brain Res 1991;546:151-4
   Google Scholar
• Heyes MP, Saito K, Jacobowitz D, Poliovirus induces indoleamine-2,3-dioxygenase and quinolinic acid synthesis in macaque brain. FASEB J 1992;6:2977-89
   Google Scholar
• Rahman A, Ting K, Cullen KM, The excitotoxin quinolinic acid induces tau phosphorylation in human neurons. PLoS One 2009;4:e6344
   PubMed Web of Science ®Google Scholar
• Schroecksnadel K, Winkler C, Sarcletti M, Parameters of soluble immune activation in vivo correlate negatively with the proliferative capacity of peripheral blood mononuclear cells in vitro in HIV-infected patients. J Acquir Immune Defic Syndr 2009;50:354-9
   Google Scholar
• Muller AJ, Prendergast GC. Marrying immunotherapy with chemotherapy: why say IDO? Cancer Res 2005;65:8065-8
   PubMed Web of Science ®Google Scholar
• Macchiarulo A, Camaioni E, Nuti R, Pellicciari R. Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease. Amino Acids 2009;37:219-29
   PubMed Web of Science ®Google Scholar
• Tan PH, Bharath AK. Manipulation of indoleamine 2,3 dioxygenase; a novel therapeutic target for treatment of diseases. Expert Opin Ther Targets 2009;13:987-1012
   PubMed Web of Science ®Google Scholar
• Sugimoto H, Oda S, Otsuki T, Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase. Proc Natl Acad Sci USA 2006;103:2611-16
   PubMed Web of Science ®Google Scholar
• Baban B, Chandler P, McCool D, Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific. J Reprod Immunol 2004;61:67-77
   PubMed Web of Science ®Google Scholar
• Cady SG, Sono M. 1-Methyl-DL-tryptophan, beta-(3-benzofuranyl)-DL-alanine (the oxygen analog of tryptophan), and beta-3-benzo(b)thienyl]-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase. Arch Biochem Biophys 1991;291:326-33
   PubMed Web of Science ®Google Scholar
• Muller AJ, Scherle PA. Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat Rev Cancer 2006;6:613-25
   PubMed Web of Science ®Google Scholar
• Muller AJ, DuHadaway JB, Donover PS, Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005;11:312-19
   PubMed Web of Science ®Google Scholar
• Hou DY, Muller AJ, Sharma MD, Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 2007;67:792-801
   PubMed Web of Science ®Google Scholar
• Lake RA, Robinson BW. Immunotherapy and chemotherapy–a practical partnership. Nat Rev Cancer 2005;5:397-405
   PubMed Web of Science ®Google Scholar
• Jia L, Schweikart K, Tomaszewski J, Toxicology and pharmacokinetics of 1-methyl-D-tryptophan: absence of toxicity due to saturating absorption. Food Chem Toxicol 2008;46:203-11
   PubMed Web of Science ®Google Scholar
• Prendergast GC, Metz R. Indoleamine 2,3-dioxygenase-2. US20090158451A1; 2009
   Google Scholar
• Chang MY, Metz R, Muller AJ, Prendergast GC. IDO2 (indoleamine 2,3-dioxygenase 2). Atlas of Genetics and Cytogenetics in Oncology and Haematology 2009. Available from: http://AtlasGeneticsOncology.org/Genes/IDO2ID44387ch8p11.html
   Google Scholar
• Honda K, Yanai H, Negishi H, IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005;434:772-7
   PubMed Web of Science ®Google Scholar
• Curti A, Pandolfi S, Valzasina B, Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. Blood 2007;109:2871-7
   PubMed Web of Science ®Google Scholar
• Lob S, Konigsrainer A, Schafer R, Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood 2008;111:2152-4
   PubMed Web of Science ®Google Scholar
• Lob S, Konigsrainer A, Zieker D, IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother 2009;58:153-57
   PubMed Web of Science ®Google Scholar
• Qian F, Villella J, Wallace PK, Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer. Cancer Res 2009;69:5498-504
   PubMed Web of Science ®Google Scholar
• Munn DH, Mellor AL. Regulation of T cell-mediated immunity by D isomers of inhibitors of indoleamine 2,3-dioxygenase. US20050186289A1; 2005
   Google Scholar
• Available from: www.newlinkgenetics.com
   Google Scholar
• Travers MT, Gow IF, Barber MC, Indoleamine 2,3-dioxygenase activity and L-tryptophan transport in human breast cancer cells. Biochim Biophys Acta 2004;1661:106-12
   PubMed Web of Science ®Google Scholar
• Kudo Y, Boyd CA. The role of L-tryptophan transport in L-tryptophan degradation by indoleamine 2,3-dioxygenase in human placental explants. J Physiol 2001;531:417-23
   PubMed Web of Science ®Google Scholar
• Agaugue S, Perrin-Cocon L, Coutant F, 1-Methyl-tryptophan can interfere with TLR signaling in dendritic cells independently of IDO activity. J Immunol 2006;177:2061-71
   PubMed Web of Science ®Google Scholar
• Munn DH, Mellor AL. Regulation of T cell-mediated immunity by D isomers of inhibitors of indoleamine 2,3-dioxygenase. US20090123420A1; 2009
   Google Scholar
• Prendergast GC, Metz R. Compositions comprising indoleamine 2,3-dioxygenase-2 and coenzyme Q inhibitors and methods of use thereof. WO2009003164A1; 2009
   Google Scholar
• Jurgens B, Hainz U, Fuchs D, Interferon-gamma triggered indoleamine 2,3-dioxygenase competence in human monocyte-derived dendritic cells induces regulatory activity in allogeneic T cells. Blood 2009; published online 25 July 2009, doi: 10.1182/blood-2008-12-195073
   Google Scholar
• Prendergast GC, Muller AJ, Duhadaway JB, Malachowski WP. Novel methods for the treatment of cancer. US20070099844A1; 2007
   Google Scholar
• Prendergast GC, Muller AJ, Duhadaway JB, Malachowski WP. Novel IDO inhibitors and methods of use. US20070173524A1; 2007
   Google Scholar
• Cheever MA. Twelve immunotherapy drugs that could cure cancers. Immunol Rev 2008;222:357-68
   PubMed Web of Science ®Google Scholar
• Munn DH, Mellor AL. Use of inhibitors of indoleamine 2,3-dioxygenase in combination with other therapeutic modalities. US20040234623A1; 2004
   Google Scholar
• Munn DH, Mellor AL. Use of inhibitors of indoleamine 2,3-dioxygenase in combination with other therapeutic modalities. US 20090081155A1; 2009
   Google Scholar
• Eguchi N, Watanabe Y, Kawanishi K, Inhibition of indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase by beta-carboline and indole derivatives. Arch Biochem Biophys 1984;232:602-9
   PubMed Web of Science ®Google Scholar
• Sono M, Cady SG. Enzyme kinetic and spectroscopic studies of inhibitor and effector interactions with indoleamine 2,3-dioxygenase. 1. Norharman and 4-phenylimidazole binding to the enzyme as inhibitors and heme ligands. Biochemistry 1989;28:5392-9
   PubMed Web of Science ®Google Scholar
• Kumar S, Jaller D, Patel B, Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase. J Med Chem 2008;51:4968-77
   PubMed Web of Science ®Google Scholar
• Gaspari P, Banerjee T, Malachowski WP, Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors. J Med Chem 2006;49:684-92
   PubMed Web of Science ®Google Scholar
• Banerjee T, Duhadaway JB, Gaspari P, A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase. Oncogene 2008;27:2851-57
   PubMed Web of Science ®Google Scholar
• Prendergast GC, Malachowski WP, Muller AJ, DuHadaway J. Novel IDO inhibitors and methods of use thereof. US20070105907A1; 2007
   Google Scholar
• Jeong YI, Jung ID, Lee JS, (-)-Epigallocatechin gallate suppresses indoleamine 2,3-dioxygenase expression in murine dendritic cells: evidences for the COX-2 and STAT1 as potential targets. Biochem Biophys Res Commun 2007;354:1004-9
   PubMed Web of Science ®Google Scholar
• Andersen RJ, Pereira A, Huang X, Indoleamine 2,3-dioxygenase (IDO) inhibitors. US200042868A1; 2009
   Google Scholar
• Pereira A, Vottero E, Roberge M, Indoleamine 2,3-dioxygenase inhibitors from the Northeastern Pacific Marine Hydroid Garveia annulata. J Nat Prod 2006;69:1496-9
   PubMed Web of Science ®Google Scholar
• Combs AP, Glass BM, Sparks RB, Yue EW. N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase. USS20080214546A1; 2008
   Google Scholar
• Kumar S, Malachowski WP, Duhadaway JB, Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem 2008;51:1706-18
   PubMed Web of Science ®Google Scholar
• Taggart WV, Matschiner JT. Metabolism of menadione-6,7-3H in the rat. Biochemistry 1969;8:1141-6
   PubMed Web of Science ®Google Scholar
• Vottero E, Balgi A, Woods K, Inhibitors of human indoleamine 2,3-dioxygenase identified with a target-based screen in yeast. Biotechnol J 2006;1:282-8
   PubMedGoogle Scholar
• Yue EW, Douty B, Wayland B, Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model. J Med Chem 2009; puulshd online 9 June 2009, doi: 10.1021/jm900518f
   Google Scholar
• Combs AP, Glass BM, Sparks RB, Yue EW. N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase. WO2008036642; 2008
   Google Scholar
• Combs AP, Zhu CW, Sparks RB. H-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase. US20080182882A1; 2008
   Google Scholar
• Combs AP, Yue EW. Amidines as modulators of indoleamine 2,3-dioxygenase. US20080146624A1; 2008
   Google Scholar
• Combs AP, Takvorian A, Zhu CW, Sparks R. N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase. US2007075598; 2007
   Google Scholar
• Combs AP, Glass BM, Sparks RB, Yue EW. N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase. WO2008036653; 2008
   Google Scholar
• Combs AP, Zhu CW, Sparks RB. N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase. WO2008058178; 2008
   Google Scholar
• Combs AP, Yue EW. Modulators of indoleamine 2,3-dioxygenase and methods of using the same. WO2006122150; 2006
   Google Scholar
• Combs AP. Amidinoheterocycles as modulators of indoleamine 2,3-dioxygenase. WO200806643; 2008
   Google Scholar
• Combs AP, Yue EW. Amidines as modulators of indoleamine 2,3-dioxygenase. WO2008036652; 2008
   Google Scholar
• Combs AP, Glass BM. N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase. WO2007095050; 2007
   Google Scholar
• Tai AW, Lien EJ, Lai MM, Khwaja TA. Novel N-hydroxyguanidine derivatives as anticancer and antiviral agents. J Med Chem 1984;27:236-8
   PubMed Web of Science ®Google Scholar
• Available from: //www.incyte.com/drugs_product_pipeline.html for more detailed information. [Last accessed 11 November 2009]
   Google Scholar
• Volgraf M, Lumb JP, Brastianos HC, Biomimetic synthesis of the IDO inhibitors exiguamine A and B. Nat Chem Biol 2008;4:535-7
   PubMed Web of Science ®Google Scholar
• Brastianos HC, Vottero E, Patrick BO, Exiguamine A, an indoleamine-2,3-dioxygenase (IDO) inhibitor isolated from the marine sponge Neopetrosia exigua. J Am Chem Soc 2006;128:16046-7
   PubMed Web of Science ®Google Scholar
• Carr G, Chung MK, Mauk AG, Andersen RJ. Synthesis of indoleamine 2,3-dioxygenase inhibitory analogues of the sponge alkaloid exiguamine A. J Med Chem 2008;51:2634-7
   PubMed Web of Science ®Google Scholar
• Andersen RJ, Leblanc M, Brastianos HC, Substituted quinone indoleamine 2,3-dioxygenae (IDO) inhibitors and synthesis and uses therefor. WO2008052352A1; 2008
   Google Scholar
• Schroecksnadel K, Winkler C, Wirleitner B, Aspirin down-regulates tryptophan degradation in stimulated human peripheral blood mononuclear cells in vitro. Clin Exp Immunol 2005;140:41-5
   PubMed Web of Science ®Google Scholar
• Girgin G, Baydar T, Ledochowski M, Immunomodulatory effects of Turkish propolis: changes in neopterin release and tryptophan degradation. Immunobiology 2009;214:129-34
   PubMedGoogle Scholar
• Nikoo S, Bozorgmehr M, Namdar Ahmadabad H, The 14kDa protein molecule isolated from garlic suppresses indoleamine 2, 3-dioxygenase metabolites in mononuclear cells in vitro. Iran J Allergy Asthma Immunol 2008;7:203-8
   PubMedGoogle Scholar
• Available from: http://www.rain-tree.com/catclaw.htm
   Google Scholar
• Winkler C, Wirleitner B, Schroecksnadel K, In vitro effects of two extracts and two pure alkaloid preparations of Uncaria tomentosa on peripheral blood mononuclear cells. Planta Med 2004;70:205-10
   PubMedGoogle Scholar
• Winkler C, Wirleitner B, Schroecksnadel K, St. John's wort (Hypericum perforatum) counteracts cytokine-induced tryptophan catabolism in vitro. Biol Chem 2004;385:1197-202
   PubMed Web of Science ®Google Scholar
• Jenny M, Santer E, Klein A, Cacao extracts suppress tryptophan degradation of mitogen-stimulated peripheral blood mononuclear cells. J Ethnopharmacol 2009;122:261-7
   PubMed Web of Science ®Google Scholar
• Jeong YI, Kim SW, Jung ID, Curcumin suppresses the induction of indoleamine 2,3-dioxygenase by blocking the Janus-activated kinase-protein kinase Cd-STAT1 signaling pathway in interferon-g-stimulated murine dendritic cells. J Biol Chem 2009;284:3700-8
   PubMed Web of Science ®Google Scholar
• Platten M, Ho PP, Youssef S, Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 2005;310:850-5
   PubMed Web of Science ®Google Scholar
• Schofield CJ, Cerundolo V. 3-Hydroxyanthranilic acid or salts thereof for treating cancer or infections. WO2009063241A1; 2009
   Google Scholar
• Selley ML, Inglis JJ, Williams RO. A method o modting B cell functioning. WO2006053390A1; 2006
   Google Scholar
• Terness P, Bauer T, Opelz G. Use of tryptophan metabolites as pharmaceutical agents. EP1369114A1; 2003
   Google Scholar
• Terness P, Chuang JJ, Opelz G. The immunoregulatory role of IDO-producing human dendritic cells revisited. Trends Immunol 2006;27:68-73
   PubMed Web of Science ®Google Scholar
• Min WP. Method of cancer treatment using siRNA silencing. US20090220582A1; 2009
   Google Scholar
• Riesenberg R, Weiler C, Spring O, Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma. Clin Cancer Res 2007;13:6993-7002
   PubMed Web of Science ®Google Scholar
• Yu WG, Yamamoto N, Takenaka H, Molecular mechanisms underlying IFN-gamma-mediated tumor growth inhibition induced during tumor immunotherapy with rIL-12. Int Immunol 1996;8:855-65
   PubMed Web of Science ®Google Scholar
• Mellor AL, Baban B, Chandler PR, Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. J Immunol 2005;175:5601-5
   PubMed Web of Science ®Google Scholar
• Chizzolini C. T cells, B cells, and polarized immune response in the pathogenesis of fibrosis and systemic sclerosis. Curr Opin Rheumatol 2008;20:707-12
   Google Scholar
• Xu H, Zhang GX, Ciric B, Rostami A. IDO: a double-edged sword for T(H)1/T(H)2 regulation. Immunol Lett 2008;121:1-6
   PubMed Web of Science ®Google Scholar
• Gurtner GJ, Stenson WF. Treatment of inflammatory bowel disease through induction of indoleamine 2,3-dioxygenase. WO2005051321; 2005
   Google Scholar
• Pawlak K, Domaniewski T, Mysliwiec M, Pawlak D. The kynurenines are associated with oxidative stress, inflammation and the prevalence of cardiovascular disease in patients with end-stage renal disease. Atherosclerosis 2009;204:309-14
   Google Scholar